Based on the LUX-Lung clinical trials, afatinib was approved for the treatment of metastatic NSCLC harboring EGFR S768I, L861Q, and/or G719X by the U.S. FDA in 2018. Here, EGFR is linked to non-small cell lung carcinoma.